Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

ZSAN Price Correlated With Financials For Zosano Pharma

Free historical financial statements for Zosano Pharma Corp. See how revenue, income, cash flow, and balance sheet financials have changed over 29 quarters since 2015. Compare with ZSAN stock chart to see long term trends.

ZSAN Stock Compared to Quarterly

ZSAN Income Statement

Revenue, Net:132000
Revenue Per Share:0.0269
Cost of Goods & Services Sold:86000
Selling, General & Admin Expense:2942000
Research & Development Expense:4481000
Total Operating Expenses:33450000
Operating Income:-33409000
Income Taxes:0
Net Income:-33409000
Earnings Per Share, Basic:-7.86
Shares Outstanding, Basic Avg:4902260

ZSAN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:250000
Net Cash from Operations:-8540000
Net Cash from Operations Per Share:-1.7421
Net Cash from Financing Activities:11091000
Property, Plant & Equipment Purchases:65000
Net Cash from Investing Activities:-65000
Net Change in Cash & Equivalents:2486000

ZSAN Balance Sheet

Cash and Cash Equivalents:13984000
Accounts Receivable, Net:null
Total Current Assets:15632000
Property, Plant & Equipment, Net:7922000
Total Assets:26445000
Accounts Payable:3720000
Total Short-Term Liabilities:9730000
Long Term Debt, Non-Current Portion:null
Total Liabilities:12392000
COMPANY PROFILE
Organization The Company

Zosano Pharma Corporation (the “Company”) is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its proprietary transdermal microneedle system (“System”).

The Company submitted a 505(b)(2) New Drug Application (“NDA”) for M207 to the U.S. Food and Drug Administration (the “FDA”) on December 20, 2019, and on October 20, 2020, the Company received a Complete Response Letter (“CRL”) from the FDA with respect to the NDA.

On January 18, 2022, the Company resubmitted its NDA to the FDA under Section 505(b)(2) of the Food, Drug, and Cosmetic Act. On February 17, 2022, the Company received a response letter from the FDA stating that they did not consider the resubmitted M207 NDA to be a complete response to the deficiencies identified in the FDA’s October 20, 2020 CRL, and that the FDA will not begin substantive review of the application until a complete response is received. The Company is evaluating its next steps in relation to the FDA's response letter.

The Company does not anticipate realizing product revenues unless and until the FDA approves the M207 NDA and the Company begins commercializing M207, which events may never occur.

Data imported from Zosano Pharma Corp SEC filings. Check original filings before making any investment decision.